⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 20, 2024Open Access

Table 2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials

Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel Fumiko Chino Victoria Serpas Higbie Christine M. Parseghian Michael J. Overman Bruce D. Minsky Charles R. Thomas Chad Tang Pavlos Msaouel Ethan B. Ludmir

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Comparison of publication rates by SEP category

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Beck et al. (2024) studied this question.

synapsesocial.com/papers/68e5bb1eb6db643587552d96 https://doi.org/10.1158/2767-9764.26788833.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
2Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
3Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
4Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
5Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024

Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024